The objective of this research was to determine the change in hepcidin levels and other biochemical markers, including total iron binding capacity (TIBC), serum iron, testosterone, and specific vitamins in the blood of individuals with β-Thalassemia. Here, 140 participants were involved in the study, of whom 110 were affected by β-thalassemia and 30 were healthy. The samples were obtained from Baqubah Teaching Hospital, the blood bank and blood donation center. The study was carried out from May 2022 to August 2022, and the patients were housed in Diyala Provence, Baquba City and its suburbs. The participants in this investigation were split into three groups: A: 55 male patients with β-thalassemia; B: 55 female patients with β-thalassemia; and C: 30 healthy individuals that were set as a control group. The findings of the study showed that the levels of HbA1 in males and females were 93.44 ± 0.71 and 93.53 ± 0.91, respectively, while the levels of HbA2 in males and females were 4.99 ± 0.59 and 5.29 ± 0.72, respectively. In contrast, the control group had HbA1 levels of 97.33 ± 0.40 in males and 97.66 ± 0.46 in females, but HbA2 levels were 2.32 ± 0.33 in males and 2.24 ± 0.24 in females. The study revealed remarkable differences (P < 0.05) between these variables. Hematological measures, such as hemoglobin concentration and percentages of mean corpuscular volume (MCV), packed cell volume (PCV), and mean corpuscular hemoglobin (MCH) were substantially reduced (P < 0.05) in β-thalassemia patients when compared to the controls. Serum iron and TIBC were significantly increased (P < 0.05), while Hepcidin levels were markedly decreased (P < 0.05) in the serum of β-thalassemia patients compared to controls. Therefore, as a conclusion the reduction of hepcidin levels and increase in iron levels are correlated with β-thalassemia and can be used as a biomarkers in monitoring β-thalassemia disease.

1. Vichinsky EP. Changing patterns of thalassemia worldwide. Annals of the New York Academy of Sciences. 2005; 1054(1): 18-24. doi: 10.1196/annals.1345.003

2. AL-dulaimy, Waseem Yousif M., Asmaa A. Hussein, Mohammed Asaad Mahdi, and Mohammed Kadhom. "In Vitro Inhibition of Xanthine Oxidase Purified from Arthritis Serum Patients by Nanocurcumin and Artemisinin Active Compounds." Molecules 28, no. 13 (2023): 5124. https://doi.org/10.3390/molecules28135124.

3. Weatherall DJ. Thalassemia as a global health problem: recent progress toward its control in the developing countries. Annals of the New York Academy of Sciences. 2010; 1202(1): 17-23. doi: 10.1111/j.1749-6632.2010.05546.x

4. Iolascon A, Andolfo I, Barcellini W, et al. Recommendations regarding splenectomy in hereditary hemolytic anemias. Haematologica. 2017; 102(8): 1304-1313. doi: 10.3324/haematol.2016.161166

5. Galanello R, Origa R. Beta-thalassemia. Orphanet Journal of Rare Diseases. 2010; 5(1). doi: 10.1186/1750-1172-5-11

6. Lahiry P, Al-Attar SA, Hegele RA. Understanding β-thalassemia with a focus on the Indian subcontinent and the Middle East. The Open Hematology Journal. 2008; 2: 21.

7. AL-dulaimy, Waseem Yousif M., Ebtehal Sabri Mohammed, Saja F. Hassuby, and Mohammed Kadhom. "Oxidative enzymes and vitamin E in ovarian cancer: Insights from a case-control study." Trends in Immunotherapy 7, no. 2 (2023): 2649. https://doi.org/10.24294/ti.v7.i2.2649.

8. Kariuki SN, Williams TN. Human genetics and malaria resistance. Human Genetics. 2020; 139(6-7): 801-811. doi: 10.1007/s00439-020-02142-6

9. Cao A, Galanello R. Beta-thalassemia. Genetics in Medicine. 2010; 12(2): 61-76. doi: 10.1097/gim.0b013e3181cd68ed

10. Pan X. Novel human pathological mutations. Gene symbol: HBB. Disease: thalassaemia β. Hum Genet. 2010; 127(4): 478.

11. Hoffbrand AV, Vyas P, Campo E, et al. Color Atlas of Clinical Hematology: Molecular and Cellular Basis of Disease, 4th ed. John Wiley and Sons; 2019.

12. Guyton AC, Hall JE. Acid-base regulation. In: Guyton AC, Hall JE, editors. Textbook of Medical Physiology, 11th ed. Saunders Elsevier; 2006. pp. 379–396.

13. Cappellini MD, Cohen A, Porter J, et al. Guidelines for the management of transfusion-dependent thalassaemia (TDT). Thalassaemia International Federation. 2021; 2: 20.

14. Papanikolaou G, Pantopoulos K. Iron metabolism and toxicity. Toxicology and Applied Pharmacology. 2005; 202(2): 199-211. doi: 10.1016/j.taap.2004.06.021

15. Papanikolaou G, Pantopoulos K. Systemic iron homeostasis and erythropoiesis. IUBMB Life. 2017; 69(6): 399-413. doi: 10.1002/iub.1629

16. Jordan JB, Poppe L, Haniu M, et al. Hepcidin Revisited, Disulfide Connectivity, Dynamics, and Structure. Journal of Biological Chemistry. 2009; 284(36): 24155-24167. doi: 10.1074/jbc.m109.017764

17. Park CH, Valore EV, Waring AJ, et al. Hepcidin, a Urinary Antimicrobial Peptide Synthesized in the Liver. Journal of Biological Chemistry. 2001; 276(11): 7806-7810. doi: 10.1074/jbc.m008922200

18. Ramos E, Kautz L, Rodriguez R, et al. Evidence for distinct pathways of hepcidin regulation by acute and chronic iron loading in mice. Hepatology. 2011; 53(4): 1333-1341. doi: 10.1002/hep.24178

19. Pak M, Lopez MA, Gabayan V, et al. Suppression of hepcidin during anemia requires erythropoietic activity. Blood. 2006; 108(12): 3730-3735. doi: 10.1182/blood-2006-06-028787

20. Liu XB, Nguyen NBH, Marquess KD, et al. Regulation of hepcidin and ferroportin expression by lipopolysaccharide in splenic macrophages. Blood Cells, Molecules, and Diseases. 2005; 35(1): 47-56. doi: 10.1016/j.bcmd.2005.04.006

21. Bekri S, Gual P, Anty R, et al. Increased Adipose Tissue Expression of Hepcidin in Severe Obesity is Independent from Diabetes and NASH. Gastroenterology. 2006; 131(3): 788-796. doi: 10.1053/j.gastro.2006.07.007

22. Baliyan M, Kumar M, Nangia A, et al. Can RBC Indices be Used as Screening Test for Beta-Thalassemia in Indian Antenatal Women? The Journal of Obstetrics and Gynecology of India. 2019; 69(6): 495-500. doi: 10.1007/s13224-019-01220-8

23. Riou J, Godart C, Hurtrel D, et al. Cation-exchange HPLC evaluated for presumptive identification of hemoglobin variants. Clinical Chemistry. 1997; 43(1): 34-39. doi: 10.1093/clinchem/43.1.34

24. Bishop ML, Fody EP, Schoeff LE. Clinical Chemistry: Principles, Procedures, Correlations, 3rd ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2005.

25. Walker PF, Barnett ED. Immigrant Medicine. St. Louis, MO: Elsevier Mosby; 2007.

26. Kato GJ, Piel FB, Reid CD, et al. Sickle cell disease. Nature Reviews Disease Primers. 2018; 4(1). doi: 10.1038/nrdp.2018.10

27. Rahim F, Saki N, Jalalai far MA. The Role of Gene Mutations Detection in Defining the Spectrum of ß – Thalassemia in Various Ethnic Regions. Human Genetic Diseases. Published online September 30, 2011. doi: 10.5772/24295

28. Grosso M, Sessa R, Puzone S, Storino MR, Izzo P. Molecular basis of thalassemia. Anemia. 2012; 4: 341–358.

29. Weatherall DJ. Phenotype—genotype relationships in monogenic disease: lessons from the thalassaemias. Nature Reviews Genetics. 2001; 2(4): 245-255. doi: 10.1038/35066048

30. Rigano P, Rodgers GP, Renda D, et al. Clinical and hematological responses to hydroxyurea in Sicilian patients with Hb S/beta-thalassemia. Hemoglobin. 2001; 25: 9-17.

31. Klei TRL, Meinderts SM, van den Berg TK, et al. From the Cradle to the Grave: The Role of Macrophages in Erythropoiesis and Erythrophagocytosis. Frontiers in Immunology. 2017; 8. doi: 10.3389/fimmu.2017.00073

32. Deplaine G, Safeukui I, Jeddi F, et al. The sensing of poorly deformable red blood cells by the human spleen can be mimicked in vitro. Blood. 2011; 117(8): e88-e95. doi: 10.1182/blood-2010-10-312801

33. Kadhim KA, Baldawi KH, Lami FH. Prevalence, Incidence, Trend, and Complications of Thalassemia in Iraq. Hemoglobin. 2017; 41(3): 164-168. doi: 10.1080/03630269.2017.1354877

34. Wadaha HA, Meshay HD, Khamees MH. Changes in coagulation status in patients with β-thalassemia in Iraq: A case-control study. Medical Journal of Babylon. 2022; 19(2): 157-161.

35. Hamamy HA, Al-Allawi NAS. Epidemiological profile of common haemoglobinopathies in Arab countries. Journal of Community Genetics. 2012; 4(2): 147-167. doi: 10.1007/s12687-012-0127-8

36. Wintrobe MM, Lee GR, Boggs DR, Bithell TC, Athens JW, Foerster J. Clinical Hematology, 7th ed. Henry Kimpton Publisher; 1976.

37. Hoffbrand AV, Lewis SM. Postgraduate Haematology, 5th ed. Saunders; 1981.

38. Zerez CR, Tanaka KR. Impaired erythrocyte nad synthesis: A metabolic abnormality in thalassemia. American Journal of Hematology. 1989; 32(1): 1-7. doi: 10.1002/ajh.2830320102

39. Yang CP, Hung IJ. Hematological data analysis in children with thalassemia trait. Journal of the Formosan Medical Association. 1991; 90(6): 586.

40. Bain BJ. Screening of antenatal patients in a multiethnic community for beta thalassaemia trait. Journal of Clinical Pathology. 1988; 41(5): 481-485. doi: 10.1136/jcp.41.5.481

41. Arcasoy A, Cavdar AO. Changes of Trace Minerals (Serum Iron, Zinc, Copper and Magnesium) in Thalassemia. Acta Haematologica. 1975; 53(6): 341-346. doi: 10.1159/000208203

42. Walker EM, Walker SM. Effects of iron overload on the immune system. Ann Clin Lab Sci. 2000;30(4):354-365.

43. Pootrakul P, Huebers HA, Finch CA, et al. Iron metabolism in thalassemia. Birth defects original article series. 1988; 23(5B): 3-8.

44. Huang YJ, Wu SG, Ou XB, Zhang L. Changes of iron metabolism indices in children with various genotypes of thalassemia. Zhongguo Dang Dai Er Ke Za Zhi. 2010; 12(2): 85-88.

45. Nemeth E, Ganz T. Hepcidin and iron-loading anemias. Haematologica. 2006; 91(6): 727-732.

46. Pasricha SR, Frazer DM, Bowden DK, et al. Transfusion suppresses erythropoiesis and increases hepcidin in adult patients with β-thalassemia major: a longitudinal study. Blood. 2013; 122(1): 124-133. doi: 10.1182/blood-2012-12-471441

47. Costin G, Kogut MD, Hyman CB, Ortega JA. Endocrine abnormalities in thalassemia major. The American Journal of Diseases of Children. 1979; 133(5): 497-502.

48. Davis RE, Icke GC, Hilton JM, Orr E. Serum thiamin, pyridoxal, cobalamin and folate concentrations in young infants. Acta Paediatrica. 1986; 75(3): 402-407. doi: 10.1111/j.1651-2227.1986.tb10221.x

49. Stabler SP, Allen RH, Savage DG, Lindenbaum J. Clinical spectrum and diagnosis of cobalamin deficiency. Blood. 1990; 76(5): 871-881. doi: 10.1182/blood.v76.5.871.871

50. Hicks JM, Cook J, Godwin ID, Soldin SJ. Vitamin B12 and folate. Pediatric reference ranges. Archives of Pathology & Laboratory Medicine. 1993; 117(7): 704-706.